HRP20161121T1 - Terapijska uporaba spojeva koji imaju objedinjenu sert, 5-ht3 i 5-ht1a aktivnost - Google Patents
Terapijska uporaba spojeva koji imaju objedinjenu sert, 5-ht3 i 5-ht1a aktivnost Download PDFInfo
- Publication number
- HRP20161121T1 HRP20161121T1 HRP20161121TT HRP20161121T HRP20161121T1 HR P20161121 T1 HRP20161121 T1 HR P20161121T1 HR P20161121T T HRP20161121T T HR P20161121TT HR P20161121 T HRP20161121 T HR P20161121T HR P20161121 T1 HRP20161121 T1 HR P20161121T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- use according
- dimethylphenylsulfanyl
- phenyl
- piperazine
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 10
- 230000000694 effects Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 5
- YQNWZWMKLDQSAC-UHFFFAOYSA-N vortioxetine Chemical compound CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 YQNWZWMKLDQSAC-UHFFFAOYSA-N 0.000 claims 5
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 208000036640 Asperger disease Diseases 0.000 claims 1
- 201000006062 Asperger syndrome Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 206010064571 Gene mutation Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 208000037820 vascular cognitive impairment Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Nutrition Science (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (9)
1. Spoj I, koji je 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazin i njegove farmaceutski prikladne soli za uporabu u liječenju bolesti odabrane između blagog kognitivnog poremećaja; vaskularne demencije, i kognitivnog poremećaja povezanog s Downovim sindromom, mutacijama tph gena, epilepsijom, traumatskom ozljedom mozga ili Aspergerovim sindromom.
2. Spoj za uporabu prema zahtjevu 1, koji je bromovodična sol 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina.
3. Spoj za uporabu prema zahtjevu 2, gdje je ta sol kristalična.
4. Spoj za uporabu prema zahtjevu 3, gdje je ta sol, naznačena time što ima glavne pikove rendgenske difrakcije praška (XRDP) na 6.89, 9.73, 13.78 i 14.62 (°2θ), svi ± 0.1 (°2θ).
5. Spoj za uporabu prema zahtjevu 4, gdje je ta sol, naznačena XRDP-om kako je prikazan na Slici 3.
6. Spoj za uporabu prema bilo kojem od zahtjeva 1-5 u pojedinačnoj dozi za oralnu primjenu od oko 1-50 mg 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina i njegovih farmaceutski prikladnih soli.
7. Spoj za uporabu prema zahtjevu 6, gdje ta pojedinačna doza sadrži između oko 1 i 20 mg bromovodične soli 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina.
8. Spoj za uporabu prema bilo kojem od zahtjeva 1-7 uz uvjet da to nije slobodna baza 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina u ne-kristaličnom obliku.
9. Spoj za uporabu prema bilo kojem od zahtjeva 1-8 za uporabu u liječenju bolesnika koji je prethodno dobivao lijek za liječenje navedene bolesti, a koji lijek je prekinut ili mu je smanjena doza zbog neželjenih dodagađaja vezanih uz san ili seksualnost.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98771007P | 2007-11-13 | 2007-11-13 | |
DKPA200701607 | 2007-11-13 | ||
US1372207P | 2007-12-14 | 2007-12-14 | |
DKPA200701788 | 2007-12-14 | ||
US9784008P | 2008-09-17 | 2008-09-17 | |
DKPA200801300 | 2008-09-17 | ||
EP11193237.2A EP2431039B1 (en) | 2007-11-13 | 2008-11-12 | Therapeutic uses of compounds having combined sert, 5-HT3 and 5-HT1A activity |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20161121T1 true HRP20161121T1 (hr) | 2017-01-27 |
Family
ID=40170671
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20120144TT HRP20120144T4 (hr) | 2007-11-13 | 2012-02-14 | Terapijske uporabe spojeva koji imaju i sert i 5-ht3 i 5-ht1a aktivnost |
HRP20161121TT HRP20161121T1 (hr) | 2007-11-13 | 2016-09-01 | Terapijska uporaba spojeva koji imaju objedinjenu sert, 5-ht3 i 5-ht1a aktivnost |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20120144TT HRP20120144T4 (hr) | 2007-11-13 | 2012-02-14 | Terapijske uporabe spojeva koji imaju i sert i 5-ht3 i 5-ht1a aktivnost |
Country Status (30)
Country | Link |
---|---|
US (5) | US9278096B2 (hr) |
EP (3) | EP2431039B1 (hr) |
JP (2) | JP5603244B2 (hr) |
KR (1) | KR101536023B1 (hr) |
CN (1) | CN102014908A (hr) |
AR (1) | AR069260A1 (hr) |
AT (1) | ATE537829T1 (hr) |
AU (1) | AU2008323390B2 (hr) |
BR (1) | BRPI0820474B8 (hr) |
CA (1) | CA2705163C (hr) |
CL (1) | CL2008003363A1 (hr) |
CO (1) | CO6270322A2 (hr) |
CY (2) | CY1112646T1 (hr) |
DK (2) | DK2219647T4 (hr) |
EA (1) | EA027783B1 (hr) |
ES (2) | ES2379419T5 (hr) |
HR (2) | HRP20120144T4 (hr) |
HU (1) | HUE029588T2 (hr) |
IL (1) | IL205466A (hr) |
LT (1) | LT2431039T (hr) |
MX (1) | MX2010004688A (hr) |
NZ (1) | NZ585247A (hr) |
PL (2) | PL2219647T3 (hr) |
PT (2) | PT2431039T (hr) |
RS (2) | RS52256B2 (hr) |
SG (1) | SG10201405001XA (hr) |
SI (2) | SI2219647T2 (hr) |
TW (1) | TW200932233A (hr) |
WO (1) | WO2009062517A1 (hr) |
ZA (1) | ZA201003350B (hr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200932233A (en) * | 2007-11-13 | 2009-08-01 | Lundbeck & Co As H | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity |
DK2470166T3 (da) * | 2009-08-24 | 2013-09-08 | Lundbeck & Co As H | Nye sammensætninger af 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazin |
TW201212918A (en) * | 2010-08-23 | 2012-04-01 | Lundbeck & Co As H | Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine |
US9708366B2 (en) * | 2011-01-27 | 2017-07-18 | Neuren Pharmaceuticals Ltd. | Treatment of fragile X syndrome using glycyl-L-2-methylprolyl-L-glutamate |
US9274127B2 (en) | 2011-07-21 | 2016-03-01 | Meijo University | Method for determining depression, kit for analyzing serotonin transporter, and kit for analyzing ubiquitinated serotonin transporter in blood |
BR112015013675B1 (pt) * | 2012-12-13 | 2022-04-26 | H. Lundbeck A/S | Composição compreendendo vortioxetina e donepezil e usos dos mesmos |
JP6323979B2 (ja) * | 2013-01-17 | 2018-05-16 | 学校法人 名城大学 | うつ病マーカー、アッセイ方法、測定方法、うつ病薬のスクリーニング方法及びキット |
WO2014191548A1 (en) * | 2013-05-31 | 2014-12-04 | Lek Pharmaceuticals D.D. | New process for the synthesis of 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine |
EP2878596A1 (en) * | 2013-11-29 | 2015-06-03 | LEK Pharmaceuticals d.d. | Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates |
ES2694352T3 (es) * | 2013-12-20 | 2018-12-20 | H. Lundbeck A/S | Uso de un antagonista del receptor opioide con actividad kappa, y vortioxetina para el tratamiento del trastorno depresivo con características melancólicas |
CN103788019B (zh) * | 2014-01-22 | 2015-10-07 | 苏州明锐医药科技有限公司 | 沃替西汀的制备方法 |
WO2015114395A1 (en) | 2014-01-31 | 2015-08-06 | Egis Gyógyszergyár Zrt. | Process for the preparation of vortioxetine salts |
EP2930171A1 (en) * | 2014-04-07 | 2015-10-14 | LEK Pharmaceuticals d.d. | Synthesis of vortioxetine via (2,4-dimethylphenyl)(2-iodophenyl)sulfane intermediate |
CN104119299B (zh) * | 2014-08-13 | 2016-08-17 | 北京蓝贝望生物医药科技股份有限公司 | 沃赛汀或沃替西汀的氢溴酸盐 |
CN104119298B (zh) * | 2014-08-13 | 2016-08-24 | 北京蓝贝望生物医药科技股份有限公司 | 氢溴酸沃赛汀或氢溴酸沃替西汀 |
CN104610195B (zh) * | 2015-01-30 | 2017-06-27 | 上虞京新药业有限公司 | 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途 |
JO3456B1 (ar) | 2015-05-13 | 2020-07-05 | H Lundbeck As | فيروتيوكسيتين بيروجلوتامات |
AU2016296205B2 (en) * | 2015-07-17 | 2021-11-11 | Centre Hospitalier Sainte Anne Paris | 5-hydroxytryptamine 1B receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation |
CA3026728A1 (en) | 2016-07-01 | 2018-01-04 | H. Lundbeck A/S | Vortioxetine dosing regimes for fast onset of antidepressant effect |
WO2021198778A1 (en) | 2020-04-03 | 2021-10-07 | H. Lundbeck A/S | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine for prevention or treatment of emotional blunting |
WO2023036820A1 (en) | 2021-09-10 | 2023-03-16 | H. Lundbeck A/S | Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine |
KR20230148676A (ko) | 2022-04-18 | 2023-10-25 | 영진약품 주식회사 | 라베프라졸 및 탄산수소나트륨을 포함하는 조성물 및 이의 용도 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
YU163075A (en) * | 1975-07-21 | 1982-05-31 | Science Union & Cie | Process for preparing new phenoxy derivatives |
US5258387A (en) | 1990-08-21 | 1993-11-02 | Hoffmann-La Roche Inc. | Tricyclic pyridone derivatives |
UA81749C2 (uk) * | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
CN100457738C (zh) * | 2001-12-20 | 2009-02-04 | H·隆德贝克有限公司 | 芳氧基苯基和芳硫基苯基衍生物 |
SI1626720T1 (sl) | 2003-04-04 | 2008-12-31 | Lundbeck & Co As H | Derivati 4-(2-fenilsulfanil-fenil)-piperidina kotzaviralci ponovnega vnosa serotonina |
US20060019938A1 (en) | 2003-12-31 | 2006-01-26 | Beer Tomasz M | Estrogen administration for treating male cognitive dysfunction or improving male cognitive function |
MX2008016141A (es) * | 2006-06-16 | 2009-02-04 | Lundbeck & Co As H | 1-[2-(2,4-dimetilfenilsulfanil)-fenil] piperazina como un compuesto con actividad combinada de recaptación de serotonina, 5-ht3 y 5-ht1a.para el tratamiento de daño cognitivo. |
TW200848411A (en) * | 2007-03-20 | 2008-12-16 | Lundbeck & Co As H | Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine |
TW200932233A (en) | 2007-11-13 | 2009-08-01 | Lundbeck & Co As H | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity |
DK2470166T3 (da) | 2009-08-24 | 2013-09-08 | Lundbeck & Co As H | Nye sammensætninger af 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazin |
-
2008
- 2008-11-03 TW TW097142306A patent/TW200932233A/zh unknown
- 2008-11-11 AR ARP080104919A patent/AR069260A1/es unknown
- 2008-11-12 CA CA2705163A patent/CA2705163C/en active Active
- 2008-11-12 PL PL08850935T patent/PL2219647T3/pl unknown
- 2008-11-12 CL CL2008003363A patent/CL2008003363A1/es unknown
- 2008-11-12 PL PL11193237.2T patent/PL2431039T3/pl unknown
- 2008-11-12 ES ES08850935T patent/ES2379419T5/es active Active
- 2008-11-12 RS RS20120087A patent/RS52256B2/sr unknown
- 2008-11-12 PT PT111932372T patent/PT2431039T/pt unknown
- 2008-11-12 BR BRPI0820474A patent/BRPI0820474B8/pt active IP Right Grant
- 2008-11-12 SG SG10201405001XA patent/SG10201405001XA/en unknown
- 2008-11-12 EA EA201070598A patent/EA027783B1/ru not_active IP Right Cessation
- 2008-11-12 KR KR1020107010492A patent/KR101536023B1/ko active IP Right Review Request
- 2008-11-12 SI SI200830548T patent/SI2219647T2/sl unknown
- 2008-11-12 US US12/741,780 patent/US9278096B2/en active Active
- 2008-11-12 AU AU2008323390A patent/AU2008323390B2/en active Active
- 2008-11-12 MX MX2010004688A patent/MX2010004688A/es active IP Right Grant
- 2008-11-12 NZ NZ585247A patent/NZ585247A/en not_active IP Right Cessation
- 2008-11-12 DK DK08850935.1T patent/DK2219647T4/da active
- 2008-11-12 ES ES11193237.2T patent/ES2591110T3/es active Active
- 2008-11-12 PT PT08850935T patent/PT2219647E/pt unknown
- 2008-11-12 DK DK11193237.2T patent/DK2431039T3/en active
- 2008-11-12 AT AT08850935T patent/ATE537829T1/de active
- 2008-11-12 LT LTEP11193237.2T patent/LT2431039T/lt unknown
- 2008-11-12 JP JP2010533436A patent/JP5603244B2/ja active Active
- 2008-11-12 EP EP11193237.2A patent/EP2431039B1/en active Active
- 2008-11-12 CN CN2008801164637A patent/CN102014908A/zh active Pending
- 2008-11-12 SI SI200831677A patent/SI2431039T1/sl unknown
- 2008-11-12 RS RS20160756A patent/RS55147B1/sr unknown
- 2008-11-12 HU HUE11193237A patent/HUE029588T2/en unknown
- 2008-11-12 EP EP16178423.6A patent/EP3115050A1/en not_active Withdrawn
- 2008-11-12 WO PCT/DK2008/050271 patent/WO2009062517A1/en active Application Filing
- 2008-11-12 EP EP08850935.1A patent/EP2219647B2/en active Active
-
2010
- 2010-04-29 IL IL205466A patent/IL205466A/en active IP Right Grant
- 2010-05-12 ZA ZA2010/03350A patent/ZA201003350B/en unknown
- 2010-05-13 CO CO10057476A patent/CO6270322A2/es not_active Application Discontinuation
-
2012
- 2012-02-14 HR HRP20120144TT patent/HRP20120144T4/hr unknown
- 2012-02-24 CY CY20121100199T patent/CY1112646T1/el unknown
-
2014
- 2014-05-14 JP JP2014100815A patent/JP5841636B2/ja active Active
-
2016
- 2016-02-12 US US15/043,167 patent/US9744166B2/en active Active
- 2016-09-01 HR HRP20161121TT patent/HRP20161121T1/hr unknown
- 2016-09-07 CY CY20161100885T patent/CY1117978T1/el unknown
-
2017
- 2017-07-27 US US15/661,392 patent/US20180161321A1/en not_active Abandoned
-
2020
- 2020-05-12 US US15/930,014 patent/US11628166B2/en active Active
-
2023
- 2023-04-04 US US18/130,749 patent/US20240082239A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20161121T1 (hr) | Terapijska uporaba spojeva koji imaju objedinjenu sert, 5-ht3 i 5-ht1a aktivnost | |
JP2018168191A5 (hr) | ||
JP2008539267A5 (hr) | ||
UA102517C2 (ru) | Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы | |
JP2008539268A5 (hr) | ||
HRP20151017T1 (hr) | Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2-(metiloksi)-3-piridinil]metansulfonamida | |
HRP20171793T1 (hr) | Farmaceutske formulacije koje sadrže kristalne oblike (r)-7-kloro-n-(kinuklidin-3-il)benzo(b)tiofen-2-karboksamid hidroklorid monohidrata | |
JP2017504611A5 (hr) | ||
JP2009536176A5 (hr) | ||
JP2021505575A5 (hr) | ||
JP2012508734A5 (hr) | ||
JP2011520981A5 (hr) | ||
RU2011108026A (ru) | Комбинированная терапия туберкулеза | |
JP2010504973A5 (hr) | ||
JP2014517050A5 (hr) | ||
JP2004522714A5 (hr) | ||
HRP20120558T1 (hr) | Kapa-selektivni antagonist opioidnih receptora | |
JP2008513510A5 (hr) | ||
HRP20130007T1 (hr) | Lijeäśenje kognitivnih poremeä†aja pomoä†u (r)-7-kloro-n-(kinuklidin-3-il)benzo[b]tiofen-2-karboksamida i njegovih farmaceutski prihvatljivih soli | |
HRP20201316T1 (hr) | Novi modulatori receptora sfingozin-fosfata | |
JP2012505257A5 (hr) | ||
HRP20090569T1 (hr) | Stabilni kristalni oblici bifeprunoks mesilata, oblici njihovog doziranja i postupak njihovog korištenja | |
JP2015520221A5 (hr) | ||
RU2019138166A (ru) | Средство для профилактики или лечения атрофии головного мозга | |
RU2004135563A (ru) | Лекарственное средство для лечения повышенной активности мочевого пузыря |